RT Journal Article
SR Electronic
T1 Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis
JF Annals of the Rheumatic Diseases
JO Ann Rheum Dis
FD BMJ Publishing Group Ltd and European League Against Rheumatism
SP 1384
OP 1387
DO 10.1136/ard.2006.063586
VO 66
IS 10
A1 Marloes W Heijstek
A1 Gecilmara C S Pileggi
A1 Evelien Zonneveld-Huijssoon
A1 Wineke Armbrust
A1 Esther P A H Hoppenreijs
A1 Cuno S P M Uiterwaal
A1 Wietse Kuis
A1 Nico M Wulffraat
YR 2007
UL http://ard.bmj.com/content/66/10/1384.abstract
AB Objective: To assess the effect of measles, mumps and rubella (MMR) vaccination on disease activity in children with juvenile idiopathic arthritis (JIA).Methods: A retrospective observational multicentre cohort study was performed in 314 patients with JIA, born between 1989 and 1996. Disease activity and medication use were compared during the period of 6 months before vaccination versus 6 months after vaccination. Disease activity was measured by joint counts, the Physician’s global assessment scale and erythrocyte sedimentation rate. Next, we compared disease activity in patients vaccinated between 8 and 9 years of age with the activity in patients who had not been vaccinated at this time (who received MMR between the ages of 9 and 10 years).Results: No increase in disease activity or medication use was seen in the 6 months after MMR vaccination (n = 207), including in patients using methotrexate (n = 49). No overt measles infections were noted. When disease activity in vaccinated patients (n = 108) was compared with activity in those not yet vaccinated (n = 86), there were no significant differences.Conclusions: The MMR booster vaccination does not seem to aggravate disease activity in JIA. This indicates that the most patients with JIA can be vaccinated safely with the MMR vaccine. A prospective study is recommended.